Protein CRABP1 as one of the possible prognosis factors in children with high-risk neuroblastoma
A. M. Stroganova,
M. V. Rubanskaya,
G. Yu. Chemeris,
S. L. Dranko,
A. I. Karseladze,
G. B. Sagoyan,
A. P. Kazantsev https://doi.org/10.21682/2311-1267-2019-6-4-48-54
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, accounting for 6—10 % of all malignant neoplasms in children. One of the fundamentally important problems for the clinician is the stratification of the risk group and the definition of treatment tactics for patients with NB. In this work, we studied the dependence of the expression of CRABP1 protein in the primary focus and tumor metastases on the type of genetic disorders (amplification of the MYCN gene, deletion of the 11q23 locus) and the effect of the therapy in patients with NB.
About the Authors
A. M. Stroganova
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Head of the Molecular Biological Laboratory of the Department of Morphological and Molecular Genetic Diagnosis of Tumors of the N.N. Trapeznikov Research Institute of Clinical Oncology.
23 Kashirskoe Shosse, Moscow, 115478
M. V. Rubanskaya
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Researcher and Pediatric Oncologist Department of Surgery No. 2 Research Institute of Pediatric Oncology and Hematology.
23 Kashirskoe Shosse, Moscow, 115478
G. Yu. Chemeris
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Biol.), Senior Researcher of the Pathology Department of the N.N. Trapeznikov Research Institute of Clinical Oncology.
23 Kashirskoe Shosse, Moscow, 115478
S. L. Dranko
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Laboratory Geneticist of Molecular Biological Laboratory of the N.N. Trapeznikov Research Institute of Clinical Oncology.
23 Kashirskoe Shosse, Moscow, 115478
A. I. Karseladze
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Leading Researcher ofthe Pathology Department of the N.N. Trapeznikov Research Institute ofClinical Oncology.
23 Kashirskoe Shosse, Moscow, 115478
G. B. Sagoyan
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Pediatric Oncologist Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin NMRCO, Graduate Student Dmitry Rogachev NMRCPHOI, SPIN-code: 6304-0159
23 Kashirskoe Shosse, Moscow, 115478; 1 Samory Mashela St., Moscow, 117997
A. P. Kazantsev
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of the Department of Surgery No. 2 Research Institute of Pediatric Oncology and Hematology.
23 Kashirskoe Shosse, Moscow, 115478
References
1. Schulte J.H., Schulte S., Heukamp L.C., Astrahantseff K., Stephan H., Fischer M., Schramm A., Eggert A. Targeted therapy for neuroblastoma: ALK inhibitors. Klin Padiatr 2013;225(6):303-8. doi: 10.1055/s-0033-1357132.
2. Park J.R., Bagatell R., London W.B., Maris J.M., Cohn S.L., Mattay K.K., Hogarty M.; COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985-93. doi: 10.1002/pbc.24433.
3. Whittle S.B., Smith V., Doherty E., Zhao S., McCarty S., Zage P.E. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017;17(4):369-86. doi: 10.1080/14737140.2017.1285230.
4. Maris J.M. Recent advances in neuroblastoma. N Engl J Med 2010;362(23):2202-11. doi:10.1056/NEJMra0804577.
5. Park J.R., Eggert A., Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011.
6. Chatten J., Shimada H., Sather H.N., Wong K.Y., Siegel S.E., Hammond G.D. Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol 1988;19(10):1187-98. doi: 10.1016/s0046-8177(88)80151-5.
7. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., Stram D.O., Gerbing R.B., Lukens J.N., Matthay K.K., Castleberry R.P. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86(2):364-72. PMID: 10421273.
8. Lastowska M., Cotterill S., Pearson A.D., Roberts P., McGuckin A., Lewis I., Bown N. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children’s Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur J Cancer 1997;33(10):1627-33. doi: 10.1016/s0959-8049(97)00282-7.
9. Stroganova A.M., Chemeris G.Yu., Chevkina E.M., Senderovich A.I., Karseladze A.I. CRABP protein 1 and its role in the process of differentiation neuroblastoma. Bulletin of the Federal State Budgetary Institution “N.N. Blokhin Russian Scientific Center” = Journal of N.N. Blokhin Russian Cancer Research Center 2016;27(2):157-63. (In Russ.).
10. Jogi A., Vaapil M., Johansson M., Pahlman S. Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors. Upsala J Med Sci 2012;117(2):217-24. doi: 10.3109/03009734.2012.659294.
11. Campbell K., Gastier-Foster J.M., Mann M., Naranjo A.H., Van Ryn C., Bagatell R., Matthay K.K., London W.B., Irwin M.S., Shimada H., Granger M.M., Hogarty M.D., Park J.R., DuBois S.G. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children’s Oncology Group. Cancer 2017;123(21):4224-35. doi: 10.1002/cncr.30873.
12. Lastowska M., Cullinane C., Variend S., Cotterill S., Bown N., O’Neill S., Mazzocco K., Roberts P., Nicholson J., Ellershaw C., Pearson A.D., Jackson M.S.; United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetics Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001;19(12):3080-90. doi: 10.1200/JCO.2001.19.12.3080.
13. Nakazawa A., Haga C., Ohira M., Okita H., Kamijo T., Nakagawara A. Correlation between the International neuroblastoma pathology classification and genomic signature in neuroblastoma. Cancer Sci 2015;106(6):766-71. doi: 10.1111/cas.12665.
14. Villamon E., Piqueras M., Mackintosh C., Alonso J., de Alava E., Navarro S., Noguera R. Comparison of different techniques for the detection of genetic risk identifying chromosomal gains and losses in neuroblastoma. Virchows Arch 2008;453(1):47-55. doi: 10.1007/s00428-008-0633-6.
15. Miyake T., Ueda Y., Matsuzaki S., Miyatake T., Yoshino K., Fujita M., Nomura T., Enomoto T., Kimura T. CRABP1-reduced expression is associated with poorer prognosis in serous and clear cell ovarian adenocarcinoma. J Cancer Res Clin Oncol 2011;137(4):715-22. doi: 10.1007/s00432-010-0930-8.
16. Attiyeh E.F., London W.B., Mosse Y.P, Wang Q., Winter C., Khazi D., McGrady P.W., Seeger R.C., Look A.T., Shimada H., Brodeur G.M., Cohn S.L., Matthay K.K., Maris J.M. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353(21):2243-53. doi: 10.1056/NEJMoa052399.
17. Spitz R., Hero B., Simon T., Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 2006;12(11):3368-73. doi: 10.1158/1078-0432.CCR-05-2495.
18. Ho N., Peng H., Mayoh C., Liu P.Y., Atmadibrata B., Marshall G.M., Li J., Liu T. Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. Cell Cycle 2018;17(6):749-58. doi: 10.1080/15384101.2017.1421875.
19. Moreau L.A., McGrady P., London W.B., Shimada H., Cohn S.L., Maris J.M., Diller L., Look A.T., George R.E. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma A Children’s Oncology Group study. Clin Cancer Res 2006;12(19):5693-7. doi: 10.1158/1078-0432.CCR-06-1500.
20. Ambros I.M., Rumpler S., Luegmayr A., Hattinger C.M., Strehl S., Kovar H., Gadner H., Ambros P.F. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation - sign of tumor cell revertance. Eur J Cancer 1997;33(12):2043-9. doi: 10.1016/s0959-8049(97)00204-9.
21. Shimizu N., Shimura T., Tanaka T. Selective elimination of acentric double minutes from cancer cells through the extrusion of micronuclei. Mutat Res 2000;448(1):81-90. doi: 10.1016/s0027-5107(00)00003-8.
22. Storlazzi C.T., Lonoce A., Guastadisegni M.C., Trombetta D., D’Addabbo P., Daniele G., L’Abbate A., Macchia G., Surace C., Kok K., Ullmann R., Purgato S., Palumbo O., Carella M., Ambros P.F., Rocchi M. Gene amplification as double minutes or homogeneously staining regions in solid tumors: Origin and structure. Genome Research 2010;20(9):1198-206. doi: 10.1101/gr.106252.110.
23. Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.F., Biedler J.L., Cheung N.K., Ross R.A. Characteristics of stem cells from human neuroblastoma cell lines and tumors. Neoplasia 2004;6(6):838-45. doi: 10.1593/neo.04310.
24. Tabakov V.Yu., Stroganova A.M., Chestkov V.V., Karseladze A.I. New feasibility of using a tissue culture technique in diagnostic oncomorphology in case of neuroblastoma and breast cancer. Arkhiv patologii = Pathology Archive 2011;73(3):34-40. (In Russ.).
25. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., Opipari A.W. NF-kB activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chemistry 2001;276(52):48921-9. doi: 10.1074/jbc.M108674200.
26. Cohn S.L., Tweddle D.A. MYCN amplification remains prognostically strong 20 years after its “clinical debut”. Eur J Cancer 2004;40(18):2639-42. doi: 10.1016/j.ejca.2004.07.025.
27. Schwab M. MYCN in neuronal tumors. Cancer Lett. 2004;204(2):179-87. doi: 10.1016/S0304-3835(03)00454-3
28. Stigliani S., Coco S., Moretti S., Oberthuer A., Fischer M., Theissen J., Gallo F., Garavent A., Berthold F., Bonassi S., Tonini G.P., Scaruffi P. High genomic instability predicts survival in metastatic high-risk neuroblastoma. Neoplasia 2012;14(9):823-32. doi: 10.1593/neo.121114
Review
For citations:
Stroganova A.M., Rubanskaya M.V., Chemeris G.Yu., Dranko S.L., Karseladze A.I., Sagoyan G.B., Kazantsev A.P. Protein CRABP1 as one of the possible prognosis factors in children with high-risk neuroblastoma. Russian Journal of Pediatric Hematology and Oncology. 2019;6(4):48-54. (In Russ.) https://doi.org/10.21682/2311-1267-2019-6-4-48-54
Views:
585
Email this article 